NEXI-002

Overview

NEXI-002 is an autologous T cell therapy that generates cytotoxic T cells directed against multiple tumor antigens. These antigens include WT1, CD138, CS1 and NY-ESO-1.

SparkCures ID 350
Developed By NexImmune
Generic Name NEXI-002
Treatment Classifications
Treatment Targets

Clinical Trials

Resources